Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-β-cyclodextrin formulations

Journal of Pharmaceutical Sciences

Volumn 96, Issue 3, 2007, Pages 644-660

  Buchanan, Charles M ^a   Buchanan, Norma L ^a   Edgar, Kevin J ^a   Little, James L ^a   Malcolm, Michael O ^a   Ruble, Karen M ^a   Wacher, Vincent J ^a   Wempe, Michael F ^a  

^a EASTMAN CHEMICAL COMPANY   (United States)

Author keywords

Bioavailability; Chronological; Complex; Electrospray mass spectrometry; Food; Formulations; Hydroxybutenyl cyclodextrin; Pharmacokinetics; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CYCLODEXTRIN DERIVATIVE; HYDROXYBUTENYL BETA CYCLODEXTRIN; NORTAMOXIFEN; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG STRUCTURE; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

EID: 33947534438     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20709     Document Type: Article

References (20)

1. Furr BJA, Jordan VC. 1984. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205.
2. Park WC, Jordan VC. 2002. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 8(2):82-88.
3. Tamoxifen citrate (Nolvadex®) product label. www.fda.gov.
4. Toivola RJ, Karjalainen AJ, Kurkela KOA, Soderwall ML, Kangas LVM, Blanco GL, Sundquist HK. 1987. Novel tri-phenyl alkane and alkene derivatives and their preparation and use. US Patent 4, 696,949.
5. Harper MJK, Walpole AL. 1967. A new derivative of triphenylethylene: Effect of implantation and mode of action in rats. J Reprod Fert 13:101-119.
6. Harper MJK, Walpole AL. 1966. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212(5057):87.
7. Bekaii TS, Perloff MD, Weemhoff JL, Greenblatt DJ. 2004. Interactions of tamoxifen, N-desmethyltamoxifen, and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos 25:283-289.
8. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. 1991. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19(1):36-43.
9. Kisanga ER, Gjerde J, Schjott J, Mellgren G, Lien EA. 2003. Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 84:361-367.
10. Fromson JM, Pearson S, Bramah S. 1973. The metabolism of tamoxifen (I.C.I. 46,474) Part I: In laboratory animals. Xenobiotica 3(11):693-709.
11. Fromson JM, Pearson S, Bramah S. 1973. The metabolism of tamoxifen (I.C.I. 46,474) Part II: In female patients. Xenobiotica 3(11):711-714.
12. Connors KA. 1997. The stability of cyclodextrin complexes in solution. Chem Rev 97:1325-1357.
13. Szejtli J. 1995. Selectivity/structure correlation in cyclodextrin chemistry. Supramol Chem 6:217-223.
14. Uekama K, Hirayama F, Irie T. 1998. Cyclodextrin drug carrier systems. Chem Rev 98:2045-2076.
15. Szejtli J. 1991. Cyclodextrins in drug formulations: Part II. Pharm Technol 15(8):24-38.
16. Buchanan CM, Alderson SR, Cleven CD, Dixon DW, Ivanyi R, Lambert JL, Lowman DW, Offerman RJ, Szejtli J, Szente L. 2002. Synthesis and characterization of water-soluble hydroxybutenyl cyclodextrins. Carbohydr Res 327(6):493-507.
17. Buchanan CM, Buchanan NL, Edgar KJ, Lambert JL, Posey-Dowty JD, Ramsey MG, Wempe MF. Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J Pharma Sci (in press).
18. Yang L, Wu N, Clement RP, Rudewicz PJ. 2004. Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of SCH 211803 in rat and monkey plasma using automated 96-well protein precipitation. J Chromatogr B 799:271-280.
19. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics. Lippincott: Williams, & Wilkins.
20. Buchanan CM, Buchanan NL, Klein S. Unpublished results.